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ABSTRACT: Lynch syndrome is a hereditary cancer syn-
drome caused by a constitutional mutation in one of the
mismatch repair genes. The implementation of predictive
testing and targeted preventative surveillance is hindered
by the frequent finding of sequence variants of uncertain
significance in these genes. We aimed to determine the
pathogenicity of previously reported variants (c.-28A>G
and c.-7C>T) within the MLH1 5′untranslated region
(UTR) in two individuals from unrelated suspected Lynch
syndrome families. We investigated whether these variants
were associated with other pathogenic alterations using
targeted high-throughput sequencing of the MLH1 locus.
We also determined their relationship to gene expression
and epigenetic alterations at the promoter. Sequencing re-
vealed that the c.-28A>G and c.-7C>T variants were the
only potentially pathogenic alterations within the MLH1
gene. In both individuals, the levels of transcription from
the variant allele were reduced to 50% compared with
the wild-type allele. Partial loss of expression occurred in
the absence of constitutional epigenetic alterations within
the MLH1 promoter. We propose that these variants may
be pathogenic due to constitutional partial loss of MLH1
expression, and that this may be associated with inter-
mediate penetrance of a Lynch syndrome phenotype. Our
findings provide further evidence of the potential impor-
tance of noncoding variants in the MLH1 5′UTR in the
pathogenesis of Lynch syndrome.
Hum Mutat 36:622–630, 2015. Published 2015 Wiley Periodi-
cals, Inc.∗
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Introduction
Lynch syndrome (MIM #120435) predisposes to the develop-
ment of colorectal, endometrial, and other cancers [Lynch and de
la Chapelle, 2003]. It is most commonly caused by constitutional
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heterozygous loss-of-function mutations in the DNA mismatch re-
pair (MMR) genes, usually MLH1 (MIM #120436) or MSH2 (MIM
#609309) [Lynch et al., 2009]. The reported mutations in Lynch
syndrome families are genetically heterogeneous and include gross
structural alterations such as deletions or inversions, [Wagner et al.,
2002] missense, nonsense or frameshift mutations, [Tavtigian et al.,
2008] splice site mutations, [Thompson et al., 2014] or variants
within MMR gene regulatory regions such as promoter regions
[Green et al., 2003]. In many cases, the functional and hence clin-
ical significance of the sequence alterations, in particular single-
nucleotide variants (SNVs) outside coding regions, is uncertain. For
these families, predictive testing and targeted preventative surveil-
lance of family members cannot be offered. A recent study reported
the classification of 2,360 constitutional MMR gene variants into
class 1 (not pathogenic), class 2 (likely not pathogenic), class 3 (un-
certain), class 4 (likely pathogenic), or class 5 (pathogenic) [Thomp-
son et al., 2014]. The finding that a large proportion (32%) of vari-
ants belonged to class 3 demonstrates the importance of collecting
further evidence about these variants.
Several class 3 variants within the MLH1 promoter have been
found in cases of suspected Lynch syndrome, namely, c.-411 -
413del, c.-432 -435del, c.-64G>T, c.-53G>T, c.-42C>T, c.-28A>G,
c.-28A>T, c.-27C>A, c.-11C>T, and c.-7C>T [Green et al., 2003;
Hitchins et al., 2011; Ward et al., 2013; Kwok et al., 2014; Thomp-
son et al., 2014]. However, for most of these variants, it is unclear
whether they abrogate MLH1 function directly or whether they are
linked to another genetic defect within MLH1. Studies of the c.-
27C>A variant provide the most compelling evidence that MLH1
promoter variants can directly affect the regulation of MLH1. This
variant segregates with colorectal cancer in multiple cancer-affected
families [Raevaara et al., 2005; Hitchins et al., 2011; Ward et al.,
2013; Kwok et al., 2014] and has been associated with reduced tran-
scriptional activity and the dominant inheritance of a mosaic con-
stitutional MLH1 epimutation [Hitchins et al., 2011]. These studies
suggest that MLH1 promoter variants may cause unbalanced consti-
tutional expression of MLH1. In support of this, the c.-411 -413del,
c.-42C>T, c.-27C>A, and c.-11C>T variants also significantly reduce
the activity of the MLH1 promoter in driving the expression of a
reporter gene [Green et al., 2003; Hitchins et al., 2011; Ward et al.,
2013]. To date, however, no analysis of the potential pathogenicity
of the c.-28A>G or c.-7C>T variants has been undertaken, despite
the fact that these variants have been described in at least two unre-
lated individuals with suspected Lynch syndrome [Lee et al., 2005;
Muller-Koch et al., 2001].
In this study, we aimed to determine the pathogenicity of the
c.-28A>G and c.-7C>T variants within the MLH1 5′ untranslated
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Figure 1. Identification of two probands with the MLH1 c.-28A>G and c.-7C>T variants from two unrelated cancer-affected families. A and B:
The pedigrees of Family 32 and Family N, respectively. Shown are the genotypes with respect to the c.-93, c.-28, c.-7, and c.655 sites, the age of
cancer onset and other family members affected by cancer. Family N showed cosegregation of the c.-28A>G and c.-7C>T variants across two
generations. See also Supp. Figure S1. Nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence.
region (UTR) in two individuals from suspected Lynch syndrome
families. We investigated whether these variants were linked to other
constitutional pathogenic alterations within or around the MLH1
gene and whether they were associated with epigenetic alterations
at the gene promoter or changes in gene expression.
Materials and Methods
Patients and Tissue Samples
Two probands (Proband 32 and Proband N; Fig. 1) with the
c.-28A>G and c.-7C>T variants (all nucleotide numbering used
throughout the manuscript is based on cDNA sequence) were
enrolled in this study in Australia (HREC/09/SVH/63 and HREC
14/169) and Norway (HREC 2014/493/REK midt). The c.-28A>G
and c.-7C>T variants studied in this manuscript have been submit-
ted to the LOVD database at http://www.lovd.nl/MLH1. At the age
of 38 years, Proband 32 had microsatellite-unstable colorectal cancer
with wild-type BRAF (MIM #164757) and loss of MLH1 and PMS2
expression (as determined by immunohistochemistry). Proband N
was a 54-year-old woman who sought advice due to a family his-
tory of colorectal neoplasia (Fig. 1). Multiplex ligation-dependent
PCR amplification (MLPA) was performed using a commercially
available kit (MRC Holland, Amsterdam, The Netherlands). No
copy-number alterations were identified in any exons of the MLH1,
PMS2 (MIM #600259), MSH2, and MSH6 (MIM #600678) genes
in either proband. Sequence alterations across the MLH1 and PMS2
genes were further assessed using long-range PCR and Sanger se-
quencing. No sequence alterations were detected in the MLH1 or
PMS2 genes except for the c.-28A>G and c.-7C>T heterozygous
variants in the MLH1 5′UTR. The following samples were avail-
able from Proband 32; fresh frozen peripheral blood mononuclear
cells (PBMCs), DNA from PBMCs, buccal, saliva, normal colon,
and formalin-fixed paraffin-embedded tumor tissue, and RNA from
PBMCs. DNA from saliva was also available from a first-degree rel-
ative of Proband 32. The following samples were available from
Proband N: DNA from PBMCs and buccal, and RNA from PBMCs.
DNA from paraffin tissue was available from a colonic adenoma
resected from the father of Proband N and used to obtain the MLH1
haplotype of this individual. RNA was available from the PBMCs
of 43 deidentified samples from healthy individuals who had do-
nated to an institutional biobank (HREC 11/160 and HC12060).
These individuals were <50 years of age (20 male) with no history of
diabetes or cancer. Fresh frozen PBMCs were available from three
of these healthy donors. The colorectal cancer cell line SW620 was
obtained from the American Type Culture Collection (ATCC) after
cell authentication testing using microsatellite and mutation anal-
ysis. Cells were maintained in Dulbecco’s modification of Eagle’s
medium supplemented with 25 mM glucose, 10% (v/v) fetal bovine
serum, 100 units penicillin, 100 μg/ml streptomycin and 2 mM glu-
tamate (Life Technologies, Carlsbad, CA) and grown at 37°C in 5%
CO2.
DNA Methylation Analysis
Bisulfite pyrosequencing of five CpG sites immediately upstream
of the MLH1 transcription initiation site was performed as de-
scribed previously [Goel et al., 2011]. Samples were analyzed in
quadruplicate. Single molecule bisulfite sequencing was performed
as described previously [Hesson et al., 2013]. All primers used in
this study are listed in Supp. Table S1.
Targeted DNA Enrichment and High-Throughput
Sequencing
We used the HaloplexTM targeted enrichment system (Agilent
Technologies, Santa Clara, CA) to sequence a 1.7 Mb region en-
compassing 15 genes (chr3: 36422675-38128073) across the MLH1
locus. Briefly, 200 ng of genomic DNA was digested with 16 differ-
ent restriction enzymes at 37°C for 30 min. Digested DNA was then
hybridized with specific biotinylated nucleotide adapters using an
initial denaturing step of 95°C for 10 min followed by hybridiza-
tion at 54°C for 16 hr. DNA-adaptor hybrids were captured using
streptavidin beads and circularized using DNA ligase. Herculase II
Fusing DNA polymerase was used to amplify the captured target
library using the following conditions: denaturing at 98°C for 2
min followed by 25 cycles of 98°C for 30 sec, 60°C for 30 sec, 72°C
for 1 min, and a final extension of 10 min at 72°C. The amplified
target library was purified using AMPure XP Kit (Beckman Coulter
Genomics, Danvers, MA) and sequenced on a HiSeq 1500 using
paired-end 2 × 100 bp TruSeq chemistry. A total of 20,709,684
sequence reads were obtained. Alignment of reads was performed
using Bowtie2 [Langmead and Salzberg, 2012] against the human
reference genome (hg19) using default parameters. This provided
an average depth of 140, with >10x coverage across 89% of the
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target region. Coverage across the MLH1 gene was >10x across 91.8%
and 82.4% of exonic and intronic DNA, respectively. Variant calling
was performed using GATK [McKenna et al., 2010] and Pindel [Ye
et al., 2009]. Variants identified by Pindel that had variable allele
ratios >0.2 and <0.8 were considered as heterozygous. Only variants
predicted by reads with phred quality scores >30, which have a 1 in
1,000 chance that the base is incorrectly called [Ewing and Green,
1998], were considered as variants. Novel variants were defined as
those not present in the 1000 genomes or SNP137 databases.
Zygosity Assessment
Quantitative DNA fragment analysis with or without prior re-
striction enzyme digest or pyrosequencing were used to identify
genotype, as indicated (Supp. Table S2). Heterozygosity at the
c.1164del1 site within the VILL gene was assessed using pyrose-
quencing (primers labeled as “VILL [exon 10]”) in Supp. Table S1.
5′ Rapid Amplification of cDNA Ends
Transcription initiation sites were identified using a 5’/3’ rapid
amplification of cDNA ends (RACE) Kit (2nd generation; Roche,
Basel, Canton of Basel-Stadt, Switzerland) as described previously
[Hesson et al., 2009]. One microgram of total RNA was treated with
DNaseI (Fermentas, Waltham, MA) and cDNA synthesized using an
antisense primer specific to MLH1 exon 11 (Supp. Table S1). Nested
PCR was performed using a second antisense primer specific to
MLH1 exon 10 in combination with a polyT-anchor primer. Dupli-
cate samples in which reverse transcriptase was omitted were assayed
to control for DNA contamination. Transcripts were characterized
by gel extraction of PCR products and single molecule sequencing.
Sequences were aligned against the human genome (hg19) and allele
specificity was determined using the c.655G>A site.
MLH1 Expression
RNA was extracted using AllPrep DNA/RNA/miRNA Universal
Kit (Qiagen, Venlo Limburg, The Netherlands) as per the manufac-
turer’s instructions. RNA quality was determined by Agilent 2100
electrophoresis bioanalyzer. cDNA was synthesized from 250 ng
of high-quality RNA (RNA integrity number [RIN] >8) using the
QuantiTect Reverse Transcription Kit (Qiagen). We excluded RNA
samples with a RIN <8.0 and generated all cDNA libraries simulta-
neously in a single batch. This approach eliminated variables such
as RNA quality and differences in the efficiency of cDNA synthesis
associated with batch effects. Allelic representation (i.e., the pro-
portion of MLH1 transcripts that originate from either allele) was
determined using PCR amplification of cDNA using primers com-
plimentary to exons 1a and 9 followed by pyrosequencing across the
c.655G>A site [Kwok et al., 2010].
Nucleosome Occupancy and Methylome Sequencing
We designed a nucleosome occupancy and methylome sequenc-
ing (NOMe-Seq) assay encompassing the transcription initiation
sites identified by 5′RACE, as well as the annotated initiation sites of
the EPM2AIP1 [NM 041805.3] and MLH1 [NM 000249.3] genes.
This 393 bp product was located c.-335 to c.58 relative to MLH1
allowing the detection of multiple nucleosomes across this pro-
moter. NOMe-Seq was performed as described previously [Kelly
et al., 2010; Taberlay et al., 2011; You et al., 2011]. This involved
harvesting intact nuclei and treating with 200 U GpC methyltrans-
ferase M.CviPl (New England Biolabs, Ipswich, MA) for 15 min at
37°C followed by termination of the reaction with an equal vol-
ume of 20 mM Tris HCl pH 7.9, 600 mM NaCl, 1% (w/v) SDS,
and 10 mM EDTA and overnight digestion with 200 μg/ml Pro-
teinase K (Ambion, Austin, TX). DNA was subsequently isolated
and bisulfite converted using EZ DNA Methylation-Gold kit (Zymo
Research, Irvine, CA). PCR amplicons were cloned using the TOPO
TA Cloning kit (Invitrogen, Carlsbad, CA) and individual molecules
isolated by colony PCR for sequencing as described previously [Hes-
son and Ward, 2014]. M.CviPI enzyme methylates accessible DNA at
GpC sites, whereas nucleosome-bound DNA is inaccessible and re-
mains refractory to GpC methylation. The promoter of the HSPA5
(MIM #138120) gene, known to be nucleosome free and accessi-
ble, was used as a control for GpC methyltransferase M.CviPl in
each sample examined. GpCpG sites were excluded from analy-
sis. Nucleosome occupancy was defined as a region 150 bp that
was inaccessible to M.CviPI. At the extreme ends of each molecule,
nucleosome-occupied DNA was identified as M.CviPI inaccessibil-
ity >75 bp (half the size of a nucleosome occupied region of DNA),
as described previously [Hesson et al., 2014]. Duplicate molecules
(those containing identical patterns of GpC methylation) were re-
moved from further analysis to prevent data misinterpretation due
to cloning or PCR bias. Molecules containing non-CpG methylation
(except in the context of GpC sites) were also discarded to eliminate
amplicons derived from incompletely converted DNA. The term oc-
cupancy refers to the proportion of molecules bearing a nucleosome
at a specific location, as described previously [Hesson et al., 2014].
Statistics
Differences in allelic balance were assessed using a two-sample
t-test.
Results
Two MLH1 5′UTR Variants Associated with Early-Onset CRC
To confirm the presence of the c.-28A>G and c.-7C>T variants, we
performed sequencing of a 1,067-bp region across the MLH1 pro-
moter (c.-960 to c.107 relative to NM 000249.3) in constitutional
DNA from both probands and identified three heterozygous vari-
ants, namely, c.-93G>A, c.-28A>G, and c.-7C>T (Supp. Fig. S1A).
No further sequence variants were identified in this region. While
the c.-93G>A is a common and benign variant, the c.-28A>G and
c.-7C>T are described as Class 3 variants of uncertain pathogenicity
in the InSiGHT database [Fokkema et al., 2011]. Data from 6,515
control exomes [Fu et al., 2013] showed both variants were present
in 4/13,006 of chromosomes tested (minor allele frequency [MAF] =
0.0003). Sequencing of individual promoter molecules determined
that these variants were present on the same allele (Supp. Fig. S1B).
Sequencing of long-range amplicons generated using cDNA derived
from PBMCs showed that in both probands the c.-93A/-28G/-7T
haplotype also contained the expressed c.655G variant in exon 8 of
the MLH1 gene, whereas the c.-93G/-28A/-7C haplotype contained
the c.655A variant.
Targeted Sequencing and Microsatellite Analysis Across
the MLH1 Locus Confirms the Lack of Deleterious Sequence
or Structural Alterations in MLH1
To determine whether the c.-28A>G and c.-7C>T variants were
in cis with another pathogenic sequence alteration within MLH1,
we employed targeted, high-throughput sequencing of constitu-
tional DNA from Proband 32. High-coverage sequencing data were
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Figure 2. Targeted sequencing confirms the lack of potentially pathogenic sequence alterations within the MLH1 gene other than the c.-28A>G
and c.-7C>T variants. A: The locations of the 15 genes within the region targeted for enrichment and sequencing, the locations and number of all
variants identified (black vertical bars), the locations and number of novel variants identified (red vertical bars), and aligned read depth across
the region (blue histogram). Shown is the region from chr3:36395082-38171759 (hg19, February 2009). B: The three variants in the MLH1 5′UTR that
were detected by targeted sequencing. No other potentially pathogenic sequence alterations were detected in the MLH1 gene. C: The locations of
sequence tagged site (STS) and SNV markers within chromosome 3 (Chr3) that were assayed for zygosity. See also Supp. Table S2. D: A schematic
of EPM2AIP1 and MLH1, indicating the locations and number of variants used to assess zygosity. Shown is the region from chr3:37026918-37093479
(hg19, February 2009). E: The location of the VILL (villin-like) c.1164del1 variant within the target region that was sequenced. See also Supp. Figures S3
and S4. B and E: The type of dbSNP137 polymorphisms is indicated by different colors with red representing nonsynonymous polymorphisms within
the coding region (including splice-site mutations); black representing intronic polymorphisms; green representing synonymous polymorphisms
within the coding region; blue representing 5′ UTR variants.
obtained over a 1.7-Mb region that consisted of exonic, intronic,
and intergenic regions of MLH1 and flanking genes (see Materials
and Methods and Fig. 2A). We detected the c.-93A/-28G/-7T and
c.-93G/-28A/-7C haplotypes within the MLH1 promoter (Fig. 2B;
Supp. Table S3), which were each confined to single 100 bp reads, as
expected. We also detected three novel intronic SNVs within MLH1
(Supp. Fig. S2; Supp. Table S3). These novel intronic variants were
located 736, 869, and 1,216 bp from the nearest MLH1 exon and
it is highly unlikely that they would contribute to splicing defects.
Therefore, no potentially pathogenic sequence alterations were de-
tected across the MLH1 gene other than the c.-28A>G and c.-7C>T
variants.
To investigate the possibility of large deletions in or flanking the
MLH1 gene, we determined zygosity at five microsatellite markers
and six SNPs within and flanking both sides of the MLH1 gene (Supp.
Table S2). These markers encompassed 20.2 Mb of DNA across
the 3p22.3-p14.3 region (Fig. 2C). All but one microsatellite marker
showed heterozygosity in constitutional DNA. Identical results were
obtained from tumor DNA. We extended this assessment of zygos-
ity using the variants identified across the MLH1 and EPM2AIP1
genes by targeted sequencing. A total of 52 sequence variants across
these genes were heterozygous, whereas only one was homozygous
(Fig. 2D). These results confirmed the presence of two intact alleles
of the MLH1 gene, and therefore the absence of MLH1 deletion, in
constitutional and tumor DNA.
Next, we examined variants in other genes and intergenic sites
across the 1.7-Mb region that was sequenced. We identified a total
of 1,452 sequence variants, comprising 1,374 SNVs and indels pre-
viously described in the 1000 genomes or SNP 137 databases and
78 novel sequence variants (Supp. Table S3). Only one of these 78
novel variants was associated with an amino acid alteration within
the coding region of a gene. This frameshift variant was a single-
nucleotide deletion (c.1164del1) within exon 10 of the VILL (villin-
like) gene that was predicted to cause the truncation of VILL protein
to p.Asp388Glu.fs.∗64 (Fig. 2E). The presence of this variant in con-
stitutional DNA from Proband 32 was confirmed by single molecule
sequencing across exon 10 (Supp. Fig. S3). Analysis of DNA from
a saliva sample obtained from a first-degree relative of Proband 32
revealed the c.1164del1 variant in VILL, and the c.-93A/-28G/-7T
variants in MLH1 were also present confirming they cosegrega-
tion on the same chromosome (Supp. Fig. S4). Data from control
exomes [Fu et al., 2013] showed that the c.1164del1 variant was
present in 1/12,520 chromosomes (MAF = 0.00008). Given the pre-
dicted pathogenicity of this variant, we determined whether it was
also present in Proband N. Pyrosequencing across the c.1164del1
site showed this variant was not present in constitutional DNA
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Figure 3. Partial loss of MLH1 expression from the variant allele. A: The locations of primers used to assess allele-specific expression of MLH1
transcripts from exon 1a. Indicated are the locations of sequence variants associated with the wild-type and variant MLH1 alleles (vertical red
bars), the locations of PCR primers within exon 1a and 9 (exon 1a F and exon 9 R, respectively), and the pyrosequencing primer used to assess
allelic balance across the c.655A>G site (Pyro R). B and C: Representative pyrograms indicating reduced expression of the variant MLH1 allele in
Proband 32 and Proband N PBMCs, respectively. Partial loss of expression from the variant allele is indicated by the reduced representation of
transcripts containing the c.655G variant. D: Compares the allelic balance of MLH1 expression in Proband 32 and Proband N with that in 12 PBMCs
from healthy donors that were informative at the c.655A>G site. ∗∗∗∗P < 0.0001 (paired t-test). Allelic balance was determined with a minimum of
three technical replicates for each sample. Data are represented as mean ± SD.
from this individual (Supp. Fig. S5A). To further define the variant
MLH1 haplotype, we determined whether the novel intronic vari-
ants described in Supp. Figure S2 cosegregated with the c.-93G>A,
c.-28A>G, c.-7C>T, and VILL c.1164del variants in the first-degree
relative of Proband 32. Neither variant was found in this individual
showing that they were located on the wild-type MLH1 allele. Both
intronic variants were also absent in Proband N. This shows that the
two probands in our study share the same ancestral variant MLH1
haplotype, and that the VILL variant in Proband 32 most likely arose
as a later event within this haplotype.
Reduced Constitutional MLH1 Expression from the Variant
Allele
The absence of potentially pathogenic sequence alterations within
or flanking the MLH1 gene other than the c.-28A>G and c.-7C>T
variants prompted us to investigate their role in regulating MLH1.
Given the location of these variants within the MLH1 5′UTR, we in-
vestigated their influence on gene expression. Allelic representation
of expression was performed by using primers complementary to
exons 1a and 9 followed by pyrosequencing across the c.655G>A site
(Fig. 3A). In Proband 32, the proportion of transcripts originating
from the variant allele was half that observed from the wild-type
allele, at 32.3%:67.7% (G:A; Fig. 3B and D). This showed there was a
50% reduction in expression from the variant allele relative to the
wild-type allele. Similar levels of allelic imbalance were observed in
the PBMCs of Proband N with the proportion of transcripts from
each allele detected at 33.7%:66.3% (G:A; Fig. 3C and D), again in-
dicating a reduction in expression from the variant allele to 50%
of the levels of the wild-type allele. These levels of allelic imbal-
ance were significantly different to the allelic balance observed in
12 control PBMCs that were also heterozygous at the c.655G>A site
(Fig. 3D; mean normal allelic balance = 45.2%:54.8% G:A, range =
49.8%:50.2%–41.6%:58.4% G:A; P < 0.0001, paired t-test). These
data show that the c.-28A>G and c.-7C>T variants are associated
with partial loss of constitutional MLH1 expression to 50% the
levels observed from the wild-type allele and that this is consistent
in two individuals.
The MLH1 CpG Island Promoter Within the Variant Allele Is
Epigenetically Unaltered
To investigate the potential causes of reduced expression from
the variant allele, we investigated the MLH1 promoter for evidence
of constitutional epigenetic changes. Routine diagnostic tests us-
ing methylation-sensitive MLPA (MS-MLPA) had suggested that
the DNA from Proband 32 was 60% methylated at one CpG site
within the MLH1 promoter, whereas six other CpG sites were un-
methylated. However, we deduced that the CpG site identified as
hypermethylated was within a HhaI restriction enzyme site (used
in the MS-MLPA assay) that was abolished by the c.-7C>T variant
(Fig. 4A). Bisulfite sequencing of individual promoter molecules
across the c.-93G>A variant confirmed the lack of methylation on
both alleles of the MLH1 promoter throughout all normal and tu-
mor tissues from Proband 32 (Fig. 4B). The lack of methylation in
constitutional DNA from both probands was also confirmed using
bisulfite pyrosequencing across five CpG dinucleotides that are asso-
ciated with the transcriptional silencing of MLH1 when methylated
(Fig. 4C and D) [Deng et al., 1999].
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Altered nucleosome occupancy, specifically around the transcrip-
tion initiation site of a gene, can correlate with gene silencing in the
absence of hypermethylation [Hesson et al., 2014]. We performed
5′RACE to map the positions of transcription initiation sites within
the MLH1 promoter in PBMCs from Proband 32. Because tran-
scription may be initiated downstream of the informative c.-93,
c.-28 or c.-7 sites, we sequenced across the c.655A>G variant to
Figure 4. See figure legend on next column.
determine the allele of transcript origin. A total of 20 wild-type
and 15 variant transcript molecules were sequenced, which collec-
tively identified 10 separate sites of transcription initiation within
exon 1a. Interestingly, 8/10 clustered within the region c.-27 to c.-3.
These initiation sites overlapped with those identified in 975 hu-
man primary cells, tissues, and cancer cell lines (Supp. Fig. S6)
[Consortium et al., 2014]. Therefore, the predominant transcrip-
tion initiation sites within the MLH1 promoter were located in the
immediate vicinity of the c.-28A>G and c.-7C>T variants. However,
comparison of the initiation sites between the variant and wild-type
alleles showed that the presence of these variants did not alter the
precise sites of transcription initiation (Fig. 4E). Next, we exam-
ined nucleosome occupancy across these initiation sites using the
informative c.-7C>T site to distinguish between the wild-type and
variant alleles. One or more of the initiation sites were accessible on
59% (22/37) of wild-type promoter molecules (Fig. 4F). By com-
parison, 50% (12/24) of variant promoter molecules were accessible
across the same sites (Fig. 4F) suggesting a slight increase in nucle-
osome occupancy. However, in PBMCs from three healthy donors
and a carcinoma cell line, all of which express high levels of MLH1,
50%–69% of molecules were accessible across the same sites show-
ing that the slight increase in nucleosome occupancy observed in
the variant allele was within the normal range (Fig. 4G). These data
showed there were no marked differences in nucleosome occupancy
across transcription initiation sites between the wild-type and vari-
ant alleles or with the same sites in normal control cells. Therefore,
despite reduced expression of the variant allele, the MLH1 promoter
is epigenetically unaltered.
Discussion
We show that two SNVs in the MLH1 promoter are associated with
partial loss of MLH1 expression in two individuals from suspected
Lynch syndrome families. Specifically, the c.-28A>G and c.-7C>T
variants were associated with 50% reduction in the abundance
Figure 4. The variant allele is not epigenetically altered at the MLH1
promoter. A: A schematic of the MLH1 and EPM2AIP1 bidirectional pro-
moter indicating the location of the CpG island (green bar), seven HhaI
sites used to detect methylation by MS-MLPA (red vertical bars), and the
sequence encompassing the c.-7C>T site. The presence of the c.-7C>T
variant abolishes a HhaI restriction site. B: Single molecule bisulfite
sequencing data of various tissues from Proband 32. The c.-93G>A site
was used to distinguish between wild-type (c.-93G) and variant (c.-93A)
MLH1 alleles. The black horizontal bar labeled “Bisulfite seq” indicates
the region analyzed. Both alleles were unmethylated in all tissues ex-
amined including tumor tissue. C and D: Representative pyrograms in-
dicating methylation levels at five CpG sites within the MLH1 promoter
in Proband 32 PBMCs and Proband N buccal DNA, respectively. The
nominal limit of quantification for this assay is 5%. E: The locations of
unique transcription initiation sites in exon 1a of the wild-type (green
box) and variant (blue box) MLH1 alleles. The c.-93, c.-28, and c.-7 sites
are indicated by the red vertical bars. F: Nucleosome occupancy across
individual promoter molecules separated according to allele of origin,
as determined by the c.-7C>T variant (yellow diamond). Black arrows in-
dicate the annotated MLH1 [NM_000249.3] or EPM2AIP1 [NM_014805.3]
transcription initiation sites, whereas green and blue arrows indicate
the locations of sites identified by 5′RACE in wild-type and variant alle-
les, respectively. Thin vertical black lines represent the positions of GpC
dinucleotides. Black circles = GpC dinucleotides methylated/accessible
to the GpC methyltransferase M.CviPI. White circles = GpC dinucleotides
unmethylated/inaccessible to GpC methyltransferase. Pink shading in-
dicates regions of accessibility 150 or >75 bp at the extreme ends of
amplicons. G: Nucleosome occupancy across the same region in MLH1-
expressing colorectal carcinoma cells and PBMCs from healthy donors.
The number of molecules sequenced is indicated at the bottom right of
each panel.
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of transcripts initiated from the variant allele when compared with
the wild-type allele. This loss of expression occurred in the context
of an intact MLH1 promoter and in the absence of any other po-
tentially pathogenic sequence alterations in or around the MLH1
gene. Though these variants are located in the immediate vicinity
of transcription initiation sites, we show that they do not alter the
precise location of these initiation sites. Finally, despite partial loss
of expression from the variant allele, we show that the c.-28A>G and
c.-7C>T variants are not associated with promoter hypermethyla-
tion or alterations in nucleosome occupancy. These findings suggest
that the c.-28A>G and c.-7C>T variants may be pathogenic due to
allelic imbalance of MLH1 expression.
There are now several reports of Lynch syndrome associated with
partial loss of MLH1 expression [Curia et al., 1999; Green et al.,
2003; Hinrichsen et al., 2013]. Curia et al. (1999) described Lynch
syndrome associated with a silent variant within exon 9 of the MLH1
gene and 50% reduction in constitutional levels of expression com-
pared with the wild-type allele. Green et al. (2003) described a c.-
42C>T variant within the MLH1 gene associated with the reduction
of promoter activity to 37% that of wild-type promoter sequence.
Furthermore, several constitutional MLH1 missense mutations that
lead to 50% or more reduction in protein levels were recently re-
classified as pathogenic [Hinrichsen et al., 2013]. In each case, loss
of the wild-type allele in tumor cells would likely lead to impaired
MMR activity due to insufficient MLH1 expression from the variant
allele. According to a recently described standardized classification
system, [Thompson et al., 2014] MMR gene variants that abrogate
gene function include those that cause-defective transcription. Our
observation that the c.-28A>G and c.-7C>T variants are associated
with partial constitutional loss of MLH1 expression provides strong
evidence that they may be pathogenic. It is possible that reduced
but not abolished MMR functionality caused by the partial loss of
MLH1 expression may give rise to an intermediate mutation rate
and the onset of cancer due to increased occurrence of somatic
mutations. A potential limitation of our study is that we assessed
MLH1 expression in PBMCs, which may not necessarily reflect the
levels of expression in colorectal mucosa. Should samples become
available, further studies could aim to determine the transcriptional
activity associated with the c.-28A>G and c.-7C>T variants in other
tissues, including colorectal mucosa. Our findings show that these
variants are associated with abrogated MLH1 function (partial loss
of expression) but this alone is insufficient to reclassify as Class 4
variants (likely pathogenic) and both remain Class 3 variants (un-
certain). Additional evidence, such as the presence of one or both
of these variants on a different background MLH1 haplotype, 2
tumors with a Lynch syndrome molecular phenotype in a carrier
or the cosegregation of these variants with Lynch syndrome will
be required to reclassify these variants as Class 4. If however, these
variants are indeed associated with intermediate penetrance, segre-
gation with Lynch syndrome is unlikely to be observed.
The variable age of onset of cancer associated with the c.-28A>G
and c.-7C>T variants was evident from the two families we investi-
gated. While Proband 32 presented with CRC aged 38 years, Proband
N was asymptomatic at 54 years. However, the father and grandfa-
ther of Proband N presented with colonic adenomas and colorectal
cancer at ages 50 and 40 years, respectively, though we were unable
to ascertain whether the grandfather had the c.-28A>G and c.-7C>T
variants. This variable penetrance may be explained by incomplete
inactivation of MLH1 expression, as described previously for the
c.-42C>T variant, which was associated with drastically different
ages of cancer onset between 35 and 76 years (average 62 years) in
a single Lynch syndrome family [Green et al., 2003]. Interestingly,
in this study, loss of heterozygosity analyses of the tumor from an
individual with the c.-42C>T variant revealed deletion of the MLH1
allele with the variant and not of the wild-type allele, as one would
expect. In our analyses, both MLH1 alleles were retained in the tu-
mor of Proband 32. These results are most likely explained by the
presence of somatic MLH1 mutations in the tumor.
Further evidence that the c.-28A>G and c.-7C>T variants are the
most likely cause of cancer predisposition was provided by our de-
tailed genetic analysis of the MLH1 locus. We combined targeted
high-throughput sequencing of the wider MLH1 locus with mi-
crosatellite marker analysis to provide high-resolution sequence and
zygosity information across the 3p14.3-p22.3 region. Collectively,
this data confirmed the lack of potentially pathogenic sequence
alterations within or flanking the MLH1 gene, other than the c.-
28A>G and c.-7C>T variants. This approach identified a frameshift
variant within the neighboring VILL gene. The cosegregation of the
c.1164del1, c.-28A>G, and c.-7C>T variants in a first-degree relative
of Proband 32 showed that they were located on the same chro-
mosome. Furthermore, their precise frequencies in control exomes
provided clues to the genetic history of this haplotype. For example,
the c.-28A>G and c.-7C>T variants have an identical MAF of 0.0003,
showing that they represent part of an ancestral haplotype. More-
over, the absence of any identifiable sequence differences on the
variant MLH1 haplotype between the two probands investigated in
our study supports the conclusion that this MLH1 haplotype orig-
inates from a common ancestor. The VILL c.1164del1 frameshift
variant has a MAF of only 0.00008 and is therefore a more recent
genetic event within this haplotype. The function of VILL is un-
known but its homology with the VIL1 (villin [MIM #193040])
gene suggests it may play a role in regulating the actin cytoskele-
ton and the formation of microvilli at the epithelial surface of the
gut. The presence of a constitutional frameshift variant in VILL in
Proband 32 raised the possibility that it might explain early-onset
cancer. However, this variant is unlikely to be the cause of cancer
predisposition because it was absent in Family N in which the c.-
28A>G and c.-7C>T variants cosegregated. Therefore, the c.-28A>G
and c.-7C>T variants are the most likely cause of predisposition to
CRC with MMR deficiency and loss of MLH1.
The InSiGHT database [Thompson et al., 2014] describes two
suspected individuals with this haplotype in addition to two cases
described previously [Muller-Koch et al., 2001; Lee et al., 2005]. One
was diagnosed with CRC aged 46 years and had a sibling who was
diagnosed with CRC aged 28 years. The proband’s tumor was MLH1
and PMS2 negative and BRAF wild-type. Separate from the c.-7C>T
and c.-28A>G variants, no constitutional mutations in MLH1, EP-
CAM, or MSH2 were found by MLPA and no expression analyses
were undertaken. The other individual with this haplotype was also
diagnosed with MLH1 negative CRC; however, no further informa-
tion is provided. Therefore, the rarity of the c.-28A>G and c.-7C>T
haplotype at the population level, but its presence in several sus-
pected Lynch syndrome individuals to date suggests it is associated
with a Lynch syndrome phenotype.
The cosegregation of these two variants makes it difficult to ascer-
tain whether both or only one are pathogenic. The c.-7C>T variant
was found in a member of a hereditary prostate cancer family who
met revised Bethesda guidelines [Fredriksson et al., 2006]. However,
the description of a case of CRC that was associated with a c.-28A>T
variant in a 29-year-old individual from a family with multiple
cancer-affected members [Isidro et al., 2003] suggests that loss of
the c.-28A nucleotide may be pathogenic. Whether the c.-28A>T
variant in this family was associated with reduced MLH1 expression
or cosegregation with disease was not determined. Furthermore, a
variant of the adjacent nucleotide (c.-27C>A) also segregates with
Lynch syndrome in several unrelated families [Hitchins et al., 2011;
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Kwok et al., 2014]. Collectively, this suggests that c.-27 and c.-28
sites are located within an important regulatory motif within the
MLH1 5′UTR. Further work to identify the DNA-binding protein
that binds to this site will help to elucidate the mechanistic basis of
how variants within the MLH1 5′UTR affect expression.
The presence of the c.-93G>A, c.-28A>G, c.-7C>T, and c.655A>G
variants in both probands allowed us to distinguish between wild-
type and variant alleles and transcripts and to investigate the mech-
anisms of reduced MLH1 expression. We conclusively demonstrate
that the variant MLH1 promoter remains unmethylated despite par-
tial loss of expression. This contradicted the pathology report from
Proband 32, which reported methylation in tumor DNA. Using sev-
eral approaches, we demonstrate that the apparent hypermethyla-
tion was an artifact caused by the c.-7C>T variant, which lies within
a recognition site of the HhaI restriction enzyme utilized as part of
the MS-MLPA assay. However, reductions in gene expression can
correlate with other chromatin changes at transcription initiation
sites, such as increased nucleosome occupancy, which can physi-
cally occlude an initiation site from the transcriptional machinery
[Jiang and Pugh, 2009]. To determine whether the variant allele
was associated with increased nucleosome occupancy, we precisely
defined sites of MLH1 transcription initiation and compared nucle-
osome occupancy between the variant and wild-type alleles using an
allele-specific NOMe-Seq assay. Our finding that the variant allele
showed no increase in nucleosome occupancy when compared with
the wild-type allele, or the MLH1 promoter in other cells express-
ing high levels of MLH1, confirmed that it remained epigenetically
unaltered. The continued recruitment of DNA-binding factors is
thought to protect CpG island promoters from nucleosome occu-
pancy [Struhl and Segal, 2013] and de novo methylation [Lienert
et al., 2011; Krebs et al., 2014]. This suggests that the variant allele
may be protected from epigenetic silencing because it retains the
ability to recruit DNA-binding proteins such as transcription fac-
tors. Due to the proximity of the c.-28A>G and c.-7C>T variants
to transcription initiation sites, we hypothesize that diminished ex-
pression may be a result of impaired ability to initiate transcription.
In summary, our study describes further cases of suspected Lynch
syndrome associated with the c.-28A>G and c.-7C>T variants. Our
analysis shows that these variants may be pathogenic due to partial
loss of MLH1 expression. These findings reinforce the potential
importance of sequence variants in the MLH1 promoter in Lynch
syndrome and the need for future studies to sequence the entire
5′UTR when searching for pathogenic sequence alterations.
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